Evidence map›Paper›PMID 39836601›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Manner.

Xuanning Chu, Jinyu Zhao, Yuting Shen, Qi Feng, Changlin Zhou, Lingman Ma, Yiran Zhou

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuanning ChuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.ORCID https://orcid.org/0009-0001-8042-4596
Jinyu ZhaoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Yuting ShenSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Qi FengSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Changlin ZhouSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Lingman MaSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Yiran ZhouDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China.ORCID https://orcid.org/0000-0001-6561-7827

Funding

Double First-Class University project CPU2022QZ09National Natural Science Foundation of China 82403887Priority Academic Program Development of Jiangsu Higher Education Institutions
6 · The paper itself

Abstract

3-Hydroxyacyl-CoA dehydratase 2 (HACD2), an obesity-related gene involved in the elongation of long-chain fatty acids, is highly expressed in pancreatic cancer (PC) and is associated with patient prognosis. Interestingly, the study reveals that HACD2 mediated the proliferation of PC cells in a dehydratase-independent manner, affecting the downstream glycolytic pathway. Mechanistically, HACD2 promotes PC cells proliferation by binding to E3 ubiquitin-protein ligase parkin (PRKN) and enhancing pyruvate kinase PKM (PKM2) dissociation from PRKN, resulting in reduced ubiquitination of PKM2 and increased dimerization of PKM2, which subsequently promote c-Myc expression and tumor growth. Moreover, HACD2 overexpression-induced PC growth is mitigated by knockdown of PKM2 or overexpression of PRKN. Furthermore, the weight loss drug orlistat, which potentially binds to HACD2, disrupted the interaction between HACD2 and PRKN and further increased the ubiquitination of PKM2. Therefore, this study elucidates the mechanism by which the obesity-related gene HACD2 regulates PC cells proliferation through a noncanonical signaling pathway, which may provide a potential new target and strategy for the individualized clinical treatment of PC.

Indexed as

Carrier ProteinsHydro-LyasesMembrane ProteinsPancreatic NeoplasmsThyroid HormonesUbiquitin-Protein LigasesAnimalsCell Line, TumorCell ProliferationDisease ProgressionHumansMiceMice, NudeThyroid Hormone-Binding ProteinsCarrier ProteinsHydro-LyasesMembrane ProteinsThyroid Hormone-Binding ProteinsThyroid HormonesUbiquitin-Protein LigasesHACD2pancreatic cancerPKM2PRKNubiquitination

Identifiers

PMID39836601
PMCPMC11904967

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.